82 results
424B3
KZIA
Kazia Therapeutics Limited
19 Apr 24
Prospectus supplement
4:30pm
in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company … not received customary and reasonable documentation with respect to such removal to its satisfaction). Nothing in this Section shall affect in any way
6-K
EX-4.1
KZIA
Kazia Therapeutics Limited
19 Apr 24
Current report (foreign)
4:26pm
in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company … not received customary and reasonable documentation with respect to such removal to its satisfaction). Nothing in this Section shall affect in any way
6-K
EX-10.1
KZIA
Kazia Therapeutics Limited
19 Apr 24
Current report (foreign)
4:26pm
Purchase Price.
Section 2.2 MECHANICS.
(a) PURCHASE NOTICE. In accordance with Section 2.1 and subject to the satisfaction of the conditions set … . The obligation of the Company hereunder to issue and sell the Purchase Notice Securities to the Investor is subject to the satisfaction of each of the conditions
424B3
KZIA
Kazia Therapeutics Limited
5 Feb 24
Prospectus supplement
4:19pm
be eligible, upon satisfaction of certain Nasdaq requirements, for an additional period of 180 calendar days to regain compliance or the ADSs may be subject … requirement. If we do not regain compliance during this period, we may be eligible, upon satisfaction of certain Nasdaq requirements
F-1
KZIA
Kazia Therapeutics Limited
31 Jan 24
Registration statement (foreign)
12:00am
not regain compliance during this period, we may be eligible, upon satisfaction of certain Nasdaq requirements, for an additional period of 180 calendar days … , we will regain compliance with the minimum bid requirement. If we do not regain compliance during this period, we may be eligible, upon satisfaction
F-3
EX-4.3
ji9k58j 2io
15 Dec 23
Shelf registration (foreign)
5:26pm
F-3
agpwr8v of6
15 Dec 23
Shelf registration (foreign)
5:26pm
6-K
EX-4.2
3phaps9ea8r6yh mz3
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-4.3
4ypvwo8wa8c lfx
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-4.4
sj954ohr7l2zji46 50
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-4.1
9a7z0mzxge9bpunwbs
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-10.1
4jfypimqnyo1x4p
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
424B5
9lb4z
4 Dec 23
Prospectus supplement for primary offering
4:05pm
6-K
EX-99.1
4dpfh55w30 1x
1 Dec 23
Kazia Therapeutics Announces $2 Million Registered Direct Offering
8:30am
6-K
EX-99.1
70k4a2871dyc hi
20 Nov 23
Kazia Announces Receipt of Nasdaq Minimum Bid Notification
4:39pm
6-K
EX-99.1
u2qnp0h
11 Oct 23
Kazia Announces Voluntary Delisting from Asx
7:35am
6-K
EX-99.1
en00oova4kv edzvz31z
12 Dec 22
Kazia Announces Receipt of Nasdaq Minimum Bid Notification
4:01pm